Added to YB: 2026-07-29
Pitch date: 2026-07-27
PYPD [bullish]
PolyPid Ltd.
Author Info
No bio for this author
Company Info
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs.
Market Cap
$74.8M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-2.16
P/E
-2.19
EV/Sales
N/A
Sector
Pharmaceuticals
Category
growth
4 Stocks I like at their current prices - PolyPid Ltd.
PYPD (added to position): Pre-rev Israeli biotech, Kynatrix drug-delivery platform. Lead candidate D-PLEX100 (antibiotic) for abdominal surgery, FDA decision Q1/27. $7.4B TAM; 5% share by 2030 = $129.5M rev, $1.55 EPS vs $3.90 price. Binary regulatory risk. Added on unjust selloff post-US distribution deal; cost basis $4.61, 2% position.
Read full article (2 min)